This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which sections of the website you find most interesting and useful. See our Cookie Policy for more information.
Strictly Necessary and Functional
These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.
Advertising
Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.
Performance
Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.
Pharma & Biotech
Coronavirus
Cannabis
Battery Metals
Psychedelics
Pharma & Biotech
Coronavirus
Cannabis
Battery Metals
Psychedelics
07:25 Wed 04 Jan 2023
Genprex Inc. (NASDAQ:GNPX) has announced that its research collaborators at the University of Pittsburgh will present preclinical data highlighting the therapeutic potential of Genprex’s gene therapy for Type 1 diabetes at the 16th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2023) being held February 22-25, 2023, in Berlin, Germany and online.
“ATTD 2023 presents an ideal opportunity for the results of this important study to be presented to the diabetes community. The data further support the potential of Genprex’s novel gene therapy being developed for the treatment of Type 1 diabetes to change the trajectory of this devastating disease,” said Dr Mark Berger, Genprex’s chief medical officer in a statement.
“Using the expression of Pdx1 and MafA transcription factors, this approach has been shown first in mice and then in non-human primate studies to lead to the creation of new beta-like cells that produce insulin and may provide long-term replacement of beta-cells,” he added.
The diabetes gene therapy approach is comprised of a novel infusion process that uses endoscopic delivery of an adeno-associated virus (AAV) vector to bring therapeutic genes directly to the pancreas.
In models of Type 1 diabetes, these genes express proteins that transform alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body’s immune system. In Type 2 diabetes, where autoimmunity is not at play, it is believed that using a similar approach the exhausted beta cells will be rejuvenated and replenished.
The presentation will be Abstract Number 203, titled ‘Pancreatic Intraductal Infusion of Adeno-Associated Virus To Treat Non-Human Primates in a Toxin-Induced Diabetes Model’. It will be delivered by Ranjeet Kalsi, representing the laboratory of Dr George Gittes, Professor of Surgery and Pediatrics and Chief of the Division of Pediatric Surgery, University of Pittsburgh School of Medicine at 1.45pm Central European Standard Time on Saturday, February 25, 2023
The abstract will be made available on the ATTD conference website at https://attd.kenes.com.
Genprex is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. The company’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options.
Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches.
Contact the author at jon.hopkins@proactiveinvestors.com
Add related topics to MyProactive
Proactive Investors Australia Pty Ltd ACN 132 787 654 (the Company, we or us) provides you with access to the content set out above, including any news, quotes, information, data, text, reports, ratings, opinions,…
Create your account: sign up and get ahead on news and events
Genprex Inc CEO Rodney Varner tells Proactive the FDA has granted Fast Track designation to the company’s lead drug candidate, REQORSA Immunogene Therapy, in combination with Merck & Co Inc (NYSE:MRK) (Merck & Co Inc (NYSE:MRK))’s Keytruda in patients with stage III or IV non-small cell lung…
Prev article
Next article
Only registered members can use this feature.
or
Copyright © Proactive Group Holdings Inc, 2023
All Rights Reserved – Proactive North America Inc., Proactive Investors LLC.
Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use.